New Over-the-Counter Dry Eye Drop Now Available to Help Estimated 40 Percent of Americans Who Suffer from Occasional or Chronic Dry Eye

Advanced Medical Optics, Inc. (AMO) (NYSE: EYE), a global leader in ophthalmic surgical devices and eye care products, today announced the U.S. introduction of blink® Tears, a new line of over-the-counter lubricating eye drops for the estimated 40 percent of Americans who suffer from occasional or chronic dry eye symptoms. AMO developed a unique, advanced formula for blink® Tears lubricating eye drops that includes a blend of ingredients naturally found in the eye. Product benefits include: long-lasting relief with less blurring of vision; up to 60-minute moisture retention time; restores tear film with each blink; improved tear film stability; adapts to an individual’s dry eye needs by thickening when the eye is open, and thinning when the eye blinks; promotion of health and well-being of the eye. "Dry eye is one of the most common disorders we see as ophthalmologists and yet it is also one of the most under-diagnosed,” said Eric D. Donnenfeld, M.D., who is in private practice with Ophthalmic Consultants of Long Island and is a trustee of Dartmouth Medical School. "This is unfortunate, because treating dry eye effectively can improve our patients' quality of vision and their quality of life.” "I believe that blink® Tears will be a significant improvement to our treatment regimen for managing the symptoms of dry eye,” continued Dr. Donnenfeld. "The unique formulation of blink® Tears distinguishes it from other currently available artificial tears because it can provide both a long duration of effect as well as superior visual clarity. We know that patients are more likely to use artificial tears as directed if they feel they are getting a longer-lasting benefit from the drop.” "The introduction of blink® Tears lubricating eye drops is our first entree into the dry eye category and marks an important expansion of AMO’s complete refractive solution of eye care products,” said AMO Chairman and CEO Jim Mazzo. "It will be used to relieve mild to moderate dry eye whether used alone or in conjunction with ophthalmic pharmaceutical therapies.” About Dry Eye Syndrome Dry eye syndrome is a common disorder of the tear film, afflicting especially those aged 40 years and older. Symptoms of dry eye may include redness, burning, itching, light sensitivity, excessive tearing, a gritty "foreign-body” feeling and dryness. It is estimated that women are twice as likely as men to suffer from dry eye, especially as they grow older. Dry eye syndrome also can be associated with other illnesses or conditions. For example, people with diabetes or auto-immune diseases, such as rheumatoid arthritis or lupus, may be more susceptible to dry eye. Certain environmental factors can also aggravate dry eye, such as living in an arid climate. The dry air on planes can also make flying uncomfortable for those with dry eye. One of the most common causes of dry eye syndrome is a dysfunction of the meibomian gland, which produces an oil that coats the eye. It is this oil, mixed with tears, which creates a healthy tear film that keeps one’s eyes properly lubricated. Without this oil, the eye compensates by producing more tears. But even with excessive tearing, a person’s eye is still left feeling dry, itchy, uncomfortable and even painful because the tear film’s moisture is out of balance. A broad set of retail grocery stores and drug stores are now selling blink® Tears lubricating eye drops. Talk to your eye care professional about sampling blink® Tears lubricating eye drops. For more information, visit www.yourhealthyeyes.com. AMO plans to launch blink® Tears lubricating eye drops in Europe in the second half of 2008. About Advanced Medical Optics, Inc. (AMO) AMO is focused on providing the full range of advanced refractive technologies and support to help eye care professionals deliver optimal vision and lifestyle experiences to patients of all ages. Products in the cataract/implant line include intraocular lenses (IOLs), phacoemulsification systems, viscoelastics, and related products used in ocular surgery. AMO owns or has the rights to such product brands as ReZoom®, Tecnis®, Clariflex®, Sensar®, and Verisyse® IOLs, Sovereign®, Sovereign® Compact and WhiteStar Signature™ phacoemulsification systems with WhiteStar® technology, Healon® viscoelastics, and the Baerveldt® glaucoma shunt. Products in the laser vision correction line include wavefront diagnostic devices, femtosecond lasers and associated patient interface devices, and excimer laser vision correction systems and treatment cards. AMO brands in the laser vision correction business include Star S4 IR®, WaveScan Wavefront®, Advanced CustomVue™, IntraLase® and IntraLasik®. Products in the eye care line include dry eye drops and contact lens disinfecting solutions, enzymatic cleaners and lens rewetting drops. Among the eye care product brands the company possesses are COMPLETE®, COMPLETE® Blink-N-Clean®, Consept®F, Consept® 1 Step, Oxysept®, UltraCare®, Ultrazyme®, Total Care™ and blink® branded products. AMO is based in Santa Ana, California, and employs approximately 4,000 worldwide. The company has operations in 24 countries and markets products in approximately 60 countries. For more information, visit the company's Website at www.amo-inc.com. Forward-Looking Statements This press release contains forward-looking statements about AMO, including statements by Dr. Donnenfeld and Mr. Mazzo and statements relating to expected product performance, trends and outcomes, as well as the expected European launch. All forward-looking statements in this press release represent AMO's judgment only as of the date of this press release. Actual results may differ from current expectations based on a number of factors such as the potential for delays in the European launch due to unexpected regulatory or manufacturing issues, or unexpected patient outcomes or experiences. Therefore, the reader is cautioned not to rely on these forward-looking statements. AMO disclaims any intent or obligation to update these forward-looking statements. Additional information concerning these and other risk factors may be found in previous press releases issued by AMO and AMO's public periodic filings with the Securities and Exchange Commission, including the discussion under the heading "Risk factors" in AMO's 2007 Form 10-K. Copies of press releases and additional information about AMO are available at www.amo-inc.com.